Net Product Revenue

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Net Product Revenue

3. Net Product Revenue

Net product revenue consists of sales of TEGSEDI and WAYLIVRA. TEGSEDI is sold in the U.S. and E.U. On May 7, 2019, we obtained regulatory approval of WAYLIVRA in Europe, following which we began to sell WAYLIVRA in the E.U.

During the three months ended March 31, 2020 and 2019, we recorded product revenue, net, of $15.2 million and $6.8 million, respectively. The following table summarizes balances and activity in each of our product revenue allowance and reserve categories for the three months ended March 31, 2020 and 2019 (in thousands):

	Chargebacks, discounts and fees			Government and other rebates			Returns		Total
Balance at December 31, 2018	$	50		$	293		$	5	$	348
Provision related to current period sales		155			375			52		582
Adjustment related to prior period sales		—			(30	)		—		(30	)
Credits or payments made during the period		(104	)		—			—		(104	)
Balance at March 31, 2019	$	101		$	638		$	57	$	796
Balance at December 31, 2019	$	270		$	1,353		$	197	$	1,820
Provision related to current period sales		470			1,621			58		2,149
Adjustment related to prior period sales		(66	)		69			—		3
Credits or payments made during the period		(498	)		(554	)		—		(1,052	)
Balance at March 31, 2020	$	176		$	2,489		$	255	$	2,920

The following table presents the balance of our receivables and contract liabilities related to net product revenue (in thousands):

	March 31, 2020		December 31, 2019
Receivables included in "Accounts receivable"	$	10,330	$	6,946
Contract liabilities included in "Accrued liabilities"		2,645		1,550